Literature DB >> 24514089

Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection.

Alexandra I Stavrakis1, Jared A Niska, Jonathan H Shahbazian, Amanda H Loftin, Romela Irene Ramos, Fabrizio Billi, Kevin P Francis, Michael Otto, Nicholas M Bernthal, Daniel Z Uslan, Lloyd S Miller.   

Abstract

The incidence of infections related to cardiac devices (such as permanent pacemakers) has been increasing out of proportion to implantation rates. As management of device infections typically requires explantation of the device, optimal prophylactic strategies are needed. Cefazolin and vancomycin are widely used as single agents for surgical prophylaxis against cardiac device-related infections. However, combination antibiotic prophylaxis may further reduce infectious complications. To model a localized subcutaneous implant-related infection, a bioluminescent strain of Staphylococcus epidermidis was inoculated onto a medical-procedure-grade titanium disc, which was placed into a subcutaneous pocket in the backs of mice. In vivo bioluminescence imaging, quantification of ex vivo CFU from the capsules and implants, variable-pressure scanning electron microscopy (VP-SEM), and neutrophil enhanced green fluorescent protein (EGFP) fluorescence in LysEGFP mice were employed to monitor the infection. This model was used to evaluate the efficacies of low- and high-dose cefazolin (50 and 200 mg/kg of body weight) and vancomycin (10 and 110 mg/kg) intravenous prophylaxis with or without rifampin (25 mg/kg). High-dose cefazolin and high-dose vancomycin treatment resulted in almost complete bacterial clearance, whereas both low-dose cefazolin and low-dose vancomycin reduced the in vivo and ex vivo bacterial burden only moderately. The addition of rifampin to low-dose cefazolin and vancomycin was highly effective in further reducing the CFU harvested from the implants. However, vancomycin-rifampin was more effective than cefazolin-rifampin in further reducing the CFU harvested from the surrounding tissue capsules. Future studies in humans will be required to determine whether the addition of rifampin has improved efficacy in preventing device-related infections in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24514089      PMCID: PMC4023771          DOI: 10.1128/AAC.01943-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  67 in total

1.  Cardiovascular implantable electronic device replacement infections and prevention: results from the REPLACE Registry.

Authors:  Daniel Z Uslan; Marye J Gleva; David K Warren; Theofanie Mela; Mina K Chung; Venkateshwar Gottipaty; Richard Borge; Dan Dan; Timothy Shinn; Kevin Mitchell; Richard G Holcomb; Jeanne E Poole
Journal:  Pacing Clin Electrophysiol       Date:  2011-11-11       Impact factor: 1.976

Review 2.  Cardiovascular implantable electrophysiological device-related infections: a review.

Authors:  Paul A Gould; Lorne J Gula; Raymond Yee; Allan C Skanes; George J Klein; Andrew D Krahn
Journal:  Curr Opin Cardiol       Date:  2011-01       Impact factor: 2.161

3.  Mouse model of chronic post-arthroplasty infection: noninvasive in vivo bioluminescence imaging to monitor bacterial burden for long-term study.

Authors:  Jonathan R Pribaz; Nicholas M Bernthal; Fabrizio Billi; John S Cho; Romela Irene Ramos; Yi Guo; Ambrose L Cheung; Kevin P Francis; Lloyd S Miller
Journal:  J Orthop Res       Date:  2011-08-11       Impact factor: 3.494

4.  Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Douglas R Osmon; Elie F Berbari; Anthony R Berendt; Daniel Lew; Werner Zimmerli; James M Steckelberg; Nalini Rao; Arlen Hanssen; Walter R Wilson
Journal:  Clin Infect Dis       Date:  2012-12-06       Impact factor: 9.079

5.  Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice.

Authors:  Jared A Niska; Jonathan H Shahbazian; Romela Irene Ramos; Jonathan R Pribaz; Fabrizio Billi; Kevin P Francis; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

6.  Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery.

Authors:  Alexandra Douglas; Andrew A Udy; Steven C Wallis; Paul Jarrett; Janine Stuart; Melissa Lassig-Smith; Renae Deans; Michael S Roberts; Kersi Taraporewalla; Jason Jenkins; Gregory Medley; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

7.  Risk factor analysis of permanent pacemaker infection.

Authors:  Muhammad R Sohail; Daniel Z Uslan; Akbar H Khan; Paul A Friedman; David L Hayes; Walter R Wilson; James M Steckelberg; Sarah M Stoner; Larry M Baddour
Journal:  Clin Infect Dis       Date:  2007-06-06       Impact factor: 9.079

8.  Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model.

Authors:  Jurriaan E M de Steenwinkel; Rob E Aarnoutse; Gerjo J de Knegt; Marian T ten Kate; Marga Teulen; Henri A Verbrugh; Martin J Boeree; Dick van Soolingen; Irma A J M Bakker-Woudenberg
Journal:  Am J Respir Crit Care Med       Date:  2013-05-15       Impact factor: 21.405

9.  Antibiotics and antiseptics to prevent infection in cardiac rhythm management device implantation surgery.

Authors:  Rabih Darouiche; Michael Mosier; Jeffrey Voigt
Journal:  Pacing Clin Electrophysiol       Date:  2012-09-04       Impact factor: 1.976

10.  Monitoring bacterial burden, inflammation and bone damage longitudinally using optical and μCT imaging in an orthopaedic implant infection in mice.

Authors:  Jared A Niska; Jeffrey A Meganck; Jonathan R Pribaz; Jonathan H Shahbazian; Ed Lim; Ning Zhang; Brad W Rice; Ali Akin; Romela Irene Ramos; Nicholas M Bernthal; Kevin P Francis; Lloyd S Miller
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

View more
  5 in total

1.  Repurposing Sitafloxacin, Prulifloxacin, Tosufloxacin, and Sisomicin as Antimicrobials Against Biofilm and Persister Cells of Pseudomonas aeruginosa.

Authors:  Pengfei She; Shijia Li; Yaqian Liu; Lanlan Xu; Linying Zhou; Xianghai Zeng; Yimin Li; Shasha Liu; Zehao Li; Zubiar Hussain; Yong Wu
Journal:  Curr Microbiol       Date:  2021-12-14       Impact factor: 2.188

2.  Estimation of Minimum Biofilm Eradication Concentration (MBEC) on In Vivo Biofilm on Orthopedic Implants in a Rodent Femoral Infection Model.

Authors:  Yu Okae; Kohei Nishitani; Akio Sakamoto; Toshiyuki Kawai; Takuya Tomizawa; Motoo Saito; Yutaka Kuroda; Shuichi Matsuda
Journal:  Front Cell Infect Microbiol       Date:  2022-07-01       Impact factor: 6.073

3.  Direct Microscopic Observation of Human Neutrophil-Staphylococcus aureus Interaction In Vitro Suggests a Potential Mechanism for Initiation of Biofilm Infection on an Implanted Medical Device.

Authors:  Niranjan Ghimire; Brian A Pettygrove; Kyler B Pallister; James Stangeland; Shelby Stanhope; Isaac Klapper; Jovanka M Voyich; Philip S Stewart
Journal:  Infect Immun       Date:  2019-11-18       Impact factor: 3.441

4.  Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection.

Authors:  Yan Hu; Vishal Hegde; Daniel Johansen; Amanda H Loftin; Erik Dworsky; Stephen D Zoller; Howard Y Park; Christopher D Hamad; George E Nelson; Kevin P Francis; Anthony Scaduto; Nicholas M Bernthal
Journal:  PLoS One       Date:  2017-02-28       Impact factor: 3.240

5.  Development of a Staphylococcus aureus reporter strain with click beetle red luciferase for enhanced in vivo imaging of experimental bacteremia and mixed infections.

Authors:  Robert J Miller; Heidi A Crosby; Katrin Schilcher; Yu Wang; Roger V Ortines; Momina Mazhar; Dustin A Dikeman; Bret L Pinsker; Isabelle D Brown; Daniel P Joyce; Jeffrey Zhang; Nathan K Archer; Haiyun Liu; Martin P Alphonse; Julie Czupryna; William R Anderson; Nicholas M Bernthal; Lea Fortuno-Miranda; Jeff W M Bulte; Kevin P Francis; Alexander R Horswill; Lloyd S Miller
Journal:  Sci Rep       Date:  2019-11-13       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.